FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004207935> ?p ?o ?g. }

• W2004207935 endingPage "S171" @default.
• W2004207935 startingPage "S164" @default.
• W2004207935 abstract "Nosocomial infections, particularly hospital-acquired pneumonia (HAP) and bacteremia, are an increasing concern in pediatric hospitals and pediatric intensive care units. Gram-positive pathogens are a leading cause of these infections in children. Linezolid is well-tolerated and as effective as vancomycin in the treatment of these infections in adults.To evaluate the clinical effectiveness and safety of iv/oral linezolid and iv vancomycin in children with resistant Gram-positive HAP or bacteremia.Hospitalized children <12 years of age were randomized 2:1 to linezolid or vancomycin. Patients received linezolid 10 mg/kg iv every 8 h with the option to change treatment to oral linezolid suspension 10 mg/kg every 8 h or iv vancomycin 10 to 15 mg/kg every 6 to 24 h. Clinical response was evaluated at follow-up. Results from an analysis of patients with HAP or bacteremia are presented.Thirty-nine patients (linezolid, 23; vancomycin, 16) with HAP and 113 patients with bacteremia (linezolid, 81; vancomycin, 32) were included in the intent-to-treat group. Clinical cure rates for clinically evaluable patients with HAP did not differ between treatment groups (linezolid, 90.0% and vancomycin, 100%; P = 0.305). No significant difference was seen in clinical cure rates in the clinically evaluable population between the linezolid and vancomycin groups for patients with catheter-related bacteremia (84.8 and 80.0%, respectively; P = 0.716) or patients with bacteremia of unknown source (79.2 and 69.2%, respectively; P = 0.501). In this subset fewer linezolid-treated patients had drug-related adverse events than did vancomycin-treated patients (19.4% vs. 28.3%; P = 0.230). Similar percentages of patients with laboratory abnormalities, including selected hematologic parameters, were seen in both treatment groups.Intravenous/oral linezolid was well-tolerated and as effective as vancomycin in treating children with resistant Gram-positive HAP or bacteremia." @default.
• W2004207935 created "2016-06-24" @default.
• W2004207935 creator A5003518248 @default.
• W2004207935 creator A5011076506 @default.
• W2004207935 creator A5013356152 @default.
• W2004207935 creator A5027976940 @default.
• W2004207935 creator A5037421650 @default.
• W2004207935 creator A5066126305 @default.
• W2004207935 creator A5073464882 @default.
• W2004207935 creator A5089430448 @default.
• W2004207935 date "2003-09-01" @default.
• W2004207935 modified "2023-10-14" @default.
• W2004207935 title "Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant Gram-positive bacterial pathogens" @default.
• W2004207935 cites W1495642555 @default.
• W2004207935 cites W1921952824 @default.
• W2004207935 cites W1990317053 @default.
• W2004207935 cites W1990448757 @default.
• W2004207935 cites W2020661402 @default.
• W2004207935 cites W2039371528 @default.
• W2004207935 cites W2092505418 @default.
• W2004207935 cites W2122008243 @default.
• W2004207935 cites W2128076923 @default.
• W2004207935 cites W2140777443 @default.
• W2004207935 cites W2149375508 @default.
• W2004207935 cites W2149703015 @default.
• W2004207935 cites W2151859311 @default.
• W2004207935 cites W2155315480 @default.
• W2004207935 cites W2156828749 @default.
• W2004207935 cites W2158150512 @default.
• W2004207935 cites W2164552925 @default.
• W2004207935 cites W2276443311 @default.
• W2004207935 cites W2329427515 @default.
• W2004207935 cites W2403978024 @default.
• W2004207935 cites W4298050013 @default.
• W2004207935 doi "https://doi.org/10.1097/01.inf.0000086956.45566.55" @default.
• W2004207935 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14520142" @default.
• W2004207935 hasPublicationYear "2003" @default.
• W2004207935 type Work @default.
• W2004207935 sameAs 2004207935 @default.
• W2004207935 citedByCount "59" @default.
• W2004207935 countsByYear W20042079352012 @default.
• W2004207935 countsByYear W20042079352013 @default.
• W2004207935 countsByYear W20042079352014 @default.
• W2004207935 countsByYear W20042079352015 @default.
• W2004207935 countsByYear W20042079352016 @default.
• W2004207935 countsByYear W20042079352017 @default.
• W2004207935 countsByYear W20042079352019 @default.
• W2004207935 countsByYear W20042079352020 @default.
• W2004207935 countsByYear W20042079352021 @default.
• W2004207935 countsByYear W20042079352022 @default.
• W2004207935 countsByYear W20042079352023 @default.
• W2004207935 crossrefType "journal-article" @default.
• W2004207935 hasAuthorship W2004207935A5003518248 @default.
• W2004207935 hasAuthorship W2004207935A5011076506 @default.
• W2004207935 hasAuthorship W2004207935A5013356152 @default.
• W2004207935 hasAuthorship W2004207935A5027976940 @default.
• W2004207935 hasAuthorship W2004207935A5037421650 @default.
• W2004207935 hasAuthorship W2004207935A5066126305 @default.
• W2004207935 hasAuthorship W2004207935A5073464882 @default.
• W2004207935 hasAuthorship W2004207935A5089430448 @default.
• W2004207935 hasBestOaLocation W20042079351 @default.
• W2004207935 hasConcept C126322002 @default.
• W2004207935 hasConcept C141071460 @default.
• W2004207935 hasConcept C2776710477 @default.
• W2004207935 hasConcept C2777914695 @default.
• W2004207935 hasConcept C2778980435 @default.
• W2004207935 hasConcept C2779443120 @default.
• W2004207935 hasConcept C2779489039 @default.
• W2004207935 hasConcept C2781414143 @default.
• W2004207935 hasConcept C501593827 @default.
• W2004207935 hasConcept C523546767 @default.
• W2004207935 hasConcept C54355233 @default.
• W2004207935 hasConcept C71924100 @default.
• W2004207935 hasConcept C86803240 @default.
• W2004207935 hasConcept C89423630 @default.
• W2004207935 hasConceptScore W2004207935C126322002 @default.
• W2004207935 hasConceptScore W2004207935C141071460 @default.
• W2004207935 hasConceptScore W2004207935C2776710477 @default.
• W2004207935 hasConceptScore W2004207935C2777914695 @default.
• W2004207935 hasConceptScore W2004207935C2778980435 @default.
• W2004207935 hasConceptScore W2004207935C2779443120 @default.
• W2004207935 hasConceptScore W2004207935C2779489039 @default.
• W2004207935 hasConceptScore W2004207935C2781414143 @default.
• W2004207935 hasConceptScore W2004207935C501593827 @default.
• W2004207935 hasConceptScore W2004207935C523546767 @default.
• W2004207935 hasConceptScore W2004207935C54355233 @default.
• W2004207935 hasConceptScore W2004207935C71924100 @default.
• W2004207935 hasConceptScore W2004207935C86803240 @default.
• W2004207935 hasConceptScore W2004207935C89423630 @default.
• W2004207935 hasIssue "9" @default.
• W2004207935 hasLocation W20042079351 @default.
• W2004207935 hasLocation W20042079352 @default.
• W2004207935 hasLocation W20042079353 @default.
• W2004207935 hasOpenAccess W2004207935 @default.
• W2004207935 hasPrimaryLocation W20042079351 @default.
• W2004207935 hasRelatedWork W2039722079 @default.
• W2004207935 hasRelatedWork W2085930500 @default.
• W2004207935 hasRelatedWork W2116203961 @default.

• next